Cargando…

IL-15 in the Combination Immunotherapy of Cancer

We completed clinical trials of rhIL-15 by bolus, subcutaneous, and continuous intravenous infusions (CIV). IL-15 administered by CIV at 2 mcg/kg/day yielded a 38-fold increase in 10- day number of circulating NK cells, a 358-fold increase in CD56(bright) NK cells and a 5.8-fold increase in CD8 T ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waldmann, Thomas A., Dubois, Sigrid, Miljkovic, Milos D., Conlon, Kevin C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248178/ https://www.ncbi.nlm.nih.gov/pubmed/32508818 http://dx.doi.org/10.3389/fimmu.2020.00868

Ejemplares similares

Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer
por: Waldmann, Thomas A., et al.
Publicado: (2019)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
por: Dubois, Sigrid P, et al.
Publicado: (2021)

A very long-acting IL-15: implications for the immunotherapy of cancer
por: Hangasky, John A, et al.
Publicado: (2022)

Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice
por: Dubois, Sigrid, et al.
Publicado: (2015)

IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models
por: Guo, Siqi, et al.
Publicado: (2021)

The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases
por: Waldmann, Thomas
Publicado: (2002)

IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability
por: Wang, T. Tiffany, et al.
Publicado: (2018)

A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma
por: Wagner, Juliane, et al.
Publicado: (2017)

Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice
por: Dubois, Sigrid, et al.
Publicado: (2021)

IL-15 and IL15RA in Osteoarthritis: Association With Symptoms and Protease Production, but Not Structural Severity
por: Warner, Sophie C., et al.
Publicado: (2020)

Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink
por: Hangasky, John A., et al.
Publicado: (2020)

Heterodimeric IL-15 in Cancer Immunotherapy
por: Bergamaschi, Cristina, et al.
Publicado: (2021)

NK Cell IL-10 Production Requires IL-15 and IL-10 Driven STAT3 Activation
por: Clark, Sarah E., et al.
Publicado: (2019)

Vaccination with Tumor Cells Expressing IL-15 and IL-15Rα Inhibit Murine Breast and Prostate Cancer
por: Morris, John C., et al.
Publicado: (2014)

Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy
por: Knudson, Karin M., et al.
Publicado: (2022)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
por: Yang, Ying, et al.
Publicado: (2020)

The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy
por: Wu, Liangliang, et al.
Publicado: (2021)

Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
por: Grenier, Jeremy M., et al.
Publicado: (2018)

IL-15Rα-Independent IL-15 Signaling in Non-NK Cell-Derived IFNγ Driven Control of Listeria monocytogenes
por: Nandi, Madhuparna, et al.
Publicado: (2021)

Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
por: Silvestre, Renata Nacasaki, et al.
Publicado: (2023)

IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels
por: Raynor, Jana, et al.
Publicado: (2013)

Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling
por: Zizzo, Gaetano, et al.
Publicado: (2022)

Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC
por: Stravokefalou, Vasiliki, et al.
Publicado: (2023)

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15
por: Rocca, Yamila Sol, et al.
Publicado: (2016)

The roles of different forms of IL-15 in human melanoma progression
por: Di Matteo, Sabina, et al.
Publicado: (2023)

A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2022)

Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies
por: Nan, Yanyang, et al.
Publicado: (2023)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

Thymic Epithelial Cell-Derived IL-15 and IL-15 Receptor α Chain Foster Local Environment for Type 1 Innate Like T Cell Development
por: Tao, Huishan, et al.
Publicado: (2021)

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
por: Morishima, Chihiro, et al.
Publicado: (2015)

IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction
por: Easom, Nicholas J. W., et al.
Publicado: (2018)

The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation
por: Heinze, Annekathrin, et al.
Publicado: (2019)

Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia
por: Daenthanasanmak, Anusara, et al.
Publicado: (2020)

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma
por: Daenthanasanmak, Anusara, et al.
Publicado: (2022)

A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy
por: Xu, Hong, et al.
Publicado: (2021)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

The future of combination immunotherapy in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2023)

Ancient Cytokine Interleukin 15-Like (IL-15L) Induces a Type 2 Immune Response
por: Yamaguchi, Takuya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_09r1isojc51d7fu1qj5sbj3ksg